Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4978287 | 0.94 | HSP90AB1 (0.76) | HSP90AB1MAPTTP53LMNA | |
| SCHEMBL4975390 | 0.93 | HSP90AB1 (0.57) | HSP90AB1MAPTTP53LMNAKDM4E | |
| SCHEMBL4976466 | 0.88 | LMNA (0.56) | HSP90AB1MAPTTP53LMNA | |
| SCHEMBL4980630 | 0.87 | HSP90AB1 (0.66) | HSP90AB1MAPTTP53LMNAKDM4E | |
| SCHEMBL4978525 | 0.86 | HSP90AB1 (0.52) | HSP90AB1MAPTTP53KDM4ETSHR | |
| SCHEMBL4978676 | 0.84 | MAPT (0.55) | HSP90AB1MAPTTP53LMNAKDM4E | |
| SCHEMBL4977576 | 0.82 | LMNA (0.65) | HSP90AB1MAPTTP53LMNA | |
| SCHEMBL4979839 | 0.81 | HSP90AB1 (0.68) | HSP90AB1MAPTLMNAKDM4E | |
| SCHEMBL4978047 | 0.81 | HSP90AB1 (0.52) | HSP90AB1MAPTKDM4ETSHR | |
| SCHEMBL4974936 | 0.80 | HSP90AB1 (0.45) | HSP90AB1MAPTKDM4ETSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | HSP90AB1 2652/4885MAPT 2301/4885TP53 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.